ELISpot & FluoroSpot Assays: Global Market Outlook to 2023, Expecting to Grow at a CAGR of 16.2%

Dublin, Dec. 13, 2018 (GLOBE NEWSWIRE) -- The "ELISpot and FluoroSpot Assay Market by Product (Assay Kit (T Cell and B Cell assay), Analyzer, Ancillary Products), Application (Transplant, Vaccines, Clinical Trials, Cancer), End User (Hospital, Labs, Research Institute) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

ELISpot and FluoroSpot Assay market to register a CAGR of 16.2% from 2018 to 2023

The ELISpot and FluoroSpot market is projected to reach USD 287 million by 2023 from USD 135 million in 2018, at a CAGR of 16.2% during the forecast period.

The rising global incidence of chronic diseases, increasing vaccine development to address the challenge of antimicrobial resistance, and technological advancements in ELISpot and FluoroSpot assay kits and analyzers, are factors expected to drive market growth during the forecast period. The use of FluoroSpot assays for multiple-analyte detection in a single well is also expected to provide opportunities for the growth of the market.

Assay Kits are expected to account for a significant share of the market in 2018

By product, the ELISpot and FluoroSpot market is segmented into assay kits, analyzers, and ancillary products. The assay kits segment is further sub-segmented by utility, type, and analyte.

In 2018, the assay kits segment is expected to account for the largest market share. This segment is also expected to grow at the highest CAGR during the forecast period. The rising incidence of chronic diseases and technological advancements are driving the growth of this product segment.

Diagnostic applications to hold the majority share in the ELISpot and FluoroSpot market in 2018

On the basis of application, the ELISpot and FluoroSpot market is segmented into research and diagnostic applications.

In 2018, the diagnostics segment is expected to account for the larger share of the ELISpot and FluoroSpot market. The large share of this segment can be attributed to the rising global prevalence of infectious diseases and the increasing use of ELISpot kits for disease diagnosis.

North America to dominate the ELISpot and FluoroSpot market in 2018

North America which includes the US and Canada, is expected to account for the largest share of the ELISpot and FluoroSpot market. The large share of this market segment can be attributed to the increasing incidence of chronic diseases. In addition to this, the increasing focus on vaccine development is driving the growth of this market.

Key Topics Covered

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders

2 Research Methodology
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 ELISpot and FluoroSpot: Market Overview
4.2 North America: ELISpot and FluoroSpot Market, By Product (2018)
4.3 Geographical Snapshot of the ELISpot and FluoroSpot Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Global Incidence of Chronic Diseases
5.2.1.2 Increasing Vaccine Development to Address the Challenge of Antimicrobial Resistance
5.2.1.3 Technological Advancements in ELISpot and FluoroSpot Assay Kits and Analyzers
5.2.2 Opportunities
5.2.2.1 Use of FluoroSpot Assays for Multiple-Analyte Detection in a Single Well
5.2.3 Challenges
5.2.3.1 Availability of Alternative Detection Technologies

6 ELISpot and FluoroSpot Market, By Product
6.1 Introduction
6.2 Assay Kits
6.2.1 Assay Kits Market, By Technique
6.2.1.1 ELISpot Assay Kits
6.2.1.1.1 Majority of Kits Available in the Market are ELISpot Kits
6.2.1.2 FluoroSpot Assay Kits
6.2.1.2.1 Increasing Demand for Multiple Analyte Detection and Technological Advancement are Driving Segmental Growth
6.2.2 Assay Kits Market, By Utility
6.2.2.1 Diagnostic Kits
6.2.2.1.1 Diagnostic Kits are Six to Eight Times Costlier Than Research Kits
6.2.2.2 Research Kits
6.2.2.2.1 Market Growth Driven By Continued Investment in Vaccine Research, Clinical Trials, and Cancer Research
6.2.3 Assay Kits Market, By Analyte
6.2.3.1 T-Cell-Based Kits
6.2.3.1.1 Low Concentrations of Infection-Released Analytes Necessitates Use of T-Cell-Based Kits
6.2.3.2 B-Cell-Based Kits
6.2.3.2.1 Detection of B-Cell-Based Antibodies is Useful to Study Cell Response Post-Infection/Vaccination
6.2.3.3 Other Analyte Kits
6.3 Analyzers
6.3.1 Adoption of Assay Kits Will Drive the Use of Analyzers
6.4 Ancillary Products
6.4.1 Market Players Such as Thermo Fisher Scientific Provide Ancillary Products

7 ELISpot and FluoroSpot Market, By Application
7.1 Introduction
7.2 Diagnostic Applications
7.2.1 Infectious Diseases
7.2.1.1 Infectious Diseases Segment to Dominate the Diagnostic Applications Market During the Forecast Period
7.2.2 Transplants
7.2.2.1 Growing Incidence of Infections Caused During Transplant Procedures are Driving the Demand for ELISpot and FluoroSpot Assays
7.3 Research Applications
7.3.1 Vaccine Development
7.3.1.1 Vaccine Development Segment to Register the Highest Growth Rate in the Forecast Period
7.3.2 Clinical Trials
7.3.2.1 Growing Number of Clinical Trials are Driving the Demand for ELISpot and FluoroSpot Assays
7.3.3 Cancer Research
7.3.3.1 Rising Global Prevalence of Cancer is Driving the Growth of the ELISpot and FluoroSpot Market

8 ELISpot and FluoroSpot Market, By End User
8.1 Introduction
8.2 Hospitals & Clinical Laboratories
8.2.1 Hospitals & Clinical Laboratories to Account for the Largest Market Share in 2018
8.3 Research Institutes
8.3.1 Research Institutes are the Fastest-Growing End Users of the ELISpot and FluoroSpot Market
8.4 Biopharmaceutical Companies
8.4.1 Biopharmaceutical Companies Use ELISpot and FluoroSpot Assays for Vaccine Development, Clinical Trials, and Cancer Research

9 ELISpot and FluoroSpot Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 The US Will Continue to Dominate the North American ELISpot and FluoroSpot Market During the Forecast Period
9.2.2 Canada
9.2.2.1 High Burden of Chronic Diseases in the Country to Drive the Adoption of ELISpot and FluoroSpot Assays
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany to Be the Fastest-Growing Country in the European ELISpot and FluoroSpot Market
9.3.2 UK
9.3.2.1 Rising Prevalence of Ncds in the UK to Drive Market Growth
9.3.3 France
9.3.3.1 Chronic Ncds Form A Key Cause of Death in France
9.3.4 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.1.1 China's Large Vaccine Industry Provides Favorable Outlook for ELISpot and FluoroSpot Assays
9.4.2 India
9.4.2.1 High Incidence of Chronic Diseases and Growing Vaccine R&D Activity Will Contribute to Market Growth
9.4.3 Japan
9.4.3.1 Chronic Ncds are Responsible for A Large Chunk of Deaths in Japan
9.4.4 Rest of Asia Pacific
9.5 Rest of the World

10 Competitive Landscape
10.1 Overview
10.2 Market Ranking Analysis, 2017
10.2.1 Top Players in Research-Use Kits Market
10.2.2 Top Players in ELISpot and FluoroSpot Analyzers Market
10.3 Key Strategies
10.3.1 Product Launches
10.3.2 Expansions
10.3.3 Agreements
10.3.4 Acquisitions
10.3.5 Patents
10.3.6 Product Approval

11 Company Profiles
11.1 Oxford Immunotec
11.2 Cellular Technology Limited (CTL)
11.3 Mabtech AB
11.4 Becton, Dickinson and Company
11.5 Abcam
11.6 Bio-Techne
11.7 Autoimmun Diagnostika GmbH
11.8 Biotech Investissement Group
11.9 Lophius Biosciences GmbH
11.10 U-Cytech Biosciences

For more information about this report visit https://www.researchandmarkets.com/research/r9zznm/elispot_and?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: 
CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Dublin, Dec. 13, 2018 (GLOBE NEWSWIRE) -- The "ELISpot and FluoroSpot Assay Market by Product (Assay Kit (T Cell and B Cell assay), Analyzer, Ancillary Products), Application (Transplant, Vaccines, Clinical Trials, Cancer), End User (Hospital, Labs, Research Institute) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

ELISpot and FluoroSpot Assay market to register a CAGR of 16.2% from 2018 to 2023

The ELISpot and FluoroSpot market is projected to reach USD 287 million by 2023 from USD 135 million in 2018, at a CAGR of 16.2% during the forecast period.

The rising global incidence of chronic diseases, increasing vaccine development to address the challenge of antimicrobial resistance, and technological advancements in ELISpot and FluoroSpot assay kits and analyzers, are factors expected to drive market growth during the forecast period. The use of FluoroSpot assays for multiple-analyte detection in a single well is also expected to provide opportunities for the growth of the market.

Assay Kits are expected to account for a significant share of the market in 2018

By product, the ELISpot and FluoroSpot market is segmented into assay kits, analyzers, and ancillary products. The assay kits segment is further sub-segmented by utility, type, and analyte.

In 2018, the assay kits segment is expected to account for the largest market share. This segment is also expected to grow at the highest CAGR during the forecast period. The rising incidence of chronic diseases and technological advancements are driving the growth of this product segment.

Diagnostic applications to hold the majority share in the ELISpot and FluoroSpot market in 2018

On the basis of application, the ELISpot and FluoroSpot market is segmented into research and diagnostic applications.

In 2018, the diagnostics segment is expected to account for the larger share of the ELISpot and FluoroSpot market. The large share of this segment can be attributed to the rising global prevalence of infectious diseases and the increasing use of ELISpot kits for disease diagnosis.

North America to dominate the ELISpot and FluoroSpot market in 2018

North America which includes the US and Canada, is expected to account for the largest share of the ELISpot and FluoroSpot market. The large share of this market segment can be attributed to the increasing incidence of chronic diseases. In addition to this, the increasing focus on vaccine development is driving the growth of this market.

Key Topics Covered

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders

2 Research Methodology
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 ELISpot and FluoroSpot: Market Overview
4.2 North America: ELISpot and FluoroSpot Market, By Product (2018)
4.3 Geographical Snapshot of the ELISpot and FluoroSpot Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Global Incidence of Chronic Diseases
5.2.1.2 Increasing Vaccine Development to Address the Challenge of Antimicrobial Resistance
5.2.1.3 Technological Advancements in ELISpot and FluoroSpot Assay Kits and Analyzers
5.2.2 Opportunities
5.2.2.1 Use of FluoroSpot Assays for Multiple-Analyte Detection in a Single Well
5.2.3 Challenges
5.2.3.1 Availability of Alternative Detection Technologies

6 ELISpot and FluoroSpot Market, By Product
6.1 Introduction
6.2 Assay Kits
6.2.1 Assay Kits Market, By Technique
6.2.1.1 ELISpot Assay Kits
6.2.1.1.1 Majority of Kits Available in the Market are ELISpot Kits
6.2.1.2 FluoroSpot Assay Kits
6.2.1.2.1 Increasing Demand for Multiple Analyte Detection and Technological Advancement are Driving Segmental Growth
6.2.2 Assay Kits Market, By Utility
6.2.2.1 Diagnostic Kits
6.2.2.1.1 Diagnostic Kits are Six to Eight Times Costlier Than Research Kits
6.2.2.2 Research Kits
6.2.2.2.1 Market Growth Driven By Continued Investment in Vaccine Research, Clinical Trials, and Cancer Research
6.2.3 Assay Kits Market, By Analyte
6.2.3.1 T-Cell-Based Kits
6.2.3.1.1 Low Concentrations of Infection-Released Analytes Necessitates Use of T-Cell-Based Kits
6.2.3.2 B-Cell-Based Kits
6.2.3.2.1 Detection of B-Cell-Based Antibodies is Useful to Study Cell Response Post-Infection/Vaccination
6.2.3.3 Other Analyte Kits
6.3 Analyzers
6.3.1 Adoption of Assay Kits Will Drive the Use of Analyzers
6.4 Ancillary Products
6.4.1 Market Players Such as Thermo Fisher Scientific Provide Ancillary Products

7 ELISpot and FluoroSpot Market, By Application
7.1 Introduction
7.2 Diagnostic Applications
7.2.1 Infectious Diseases
7.2.1.1 Infectious Diseases Segment to Dominate the Diagnostic Applications Market During the Forecast Period
7.2.2 Transplants
7.2.2.1 Growing Incidence of Infections Caused During Transplant Procedures are Driving the Demand for ELISpot and FluoroSpot Assays
7.3 Research Applications
7.3.1 Vaccine Development
7.3.1.1 Vaccine Development Segment to Register the Highest Growth Rate in the Forecast Period
7.3.2 Clinical Trials
7.3.2.1 Growing Number of Clinical Trials are Driving the Demand for ELISpot and FluoroSpot Assays
7.3.3 Cancer Research
7.3.3.1 Rising Global Prevalence of Cancer is Driving the Growth of the ELISpot and FluoroSpot Market

8 ELISpot and FluoroSpot Market, By End User
8.1 Introduction
8.2 Hospitals & Clinical Laboratories
8.2.1 Hospitals & Clinical Laboratories to Account for the Largest Market Share in 2018
8.3 Research Institutes
8.3.1 Research Institutes are the Fastest-Growing End Users of the ELISpot and FluoroSpot Market
8.4 Biopharmaceutical Companies
8.4.1 Biopharmaceutical Companies Use ELISpot and FluoroSpot Assays for Vaccine Development, Clinical Trials, and Cancer Research

9 ELISpot and FluoroSpot Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 The US Will Continue to Dominate the North American ELISpot and FluoroSpot Market During the Forecast Period
9.2.2 Canada
9.2.2.1 High Burden of Chronic Diseases in the Country to Drive the Adoption of ELISpot and FluoroSpot Assays
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany to Be the Fastest-Growing Country in the European ELISpot and FluoroSpot Market
9.3.2 UK
9.3.2.1 Rising Prevalence of Ncds in the UK to Drive Market Growth
9.3.3 France
9.3.3.1 Chronic Ncds Form A Key Cause of Death in France
9.3.4 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.1.1 China's Large Vaccine Industry Provides Favorable Outlook for ELISpot and FluoroSpot Assays
9.4.2 India
9.4.2.1 High Incidence of Chronic Diseases and Growing Vaccine R&D Activity Will Contribute to Market Growth
9.4.3 Japan
9.4.3.1 Chronic Ncds are Responsible for A Large Chunk of Deaths in Japan
9.4.4 Rest of Asia Pacific
9.5 Rest of the World

10 Competitive Landscape
10.1 Overview
10.2 Market Ranking Analysis, 2017
10.2.1 Top Players in Research-Use Kits Market
10.2.2 Top Players in ELISpot and FluoroSpot Analyzers Market
10.3 Key Strategies
10.3.1 Product Launches
10.3.2 Expansions
10.3.3 Agreements
10.3.4 Acquisitions
10.3.5 Patents
10.3.6 Product Approval

11 Company Profiles
11.1 Oxford Immunotec
11.2 Cellular Technology Limited (CTL)
11.3 Mabtech AB
11.4 Becton, Dickinson and Company
11.5 Abcam
11.6 Bio-Techne
11.7 Autoimmun Diagnostika GmbH
11.8 Biotech Investissement Group
11.9 Lophius Biosciences GmbH
11.10 U-Cytech Biosciences

For more information about this report visit https://www.researchandmarkets.com/research/r9zznm/elispot_and?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: 
CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Ads